Closely-held PharmaJet has announced a strategic partnership with Scancell Holdings (AIM:SCLP) to supply its Stratis Intramuscular (IM) Needle-free Injection System for delivery of Scancell’s advanced melanoma DNA vaccine (Immunobody SCIB1/SCIB1+) for both clinical development and commercial use.
Under the agreement, PharmaJet will receive development and regulatory milestone payments, as well as royalties on commercial sales of the combined Stratis and the advanced melanoma vaccine. Scancell will be responsible for the clinical and regulatory development as well the commercialization of the combined product.
The FDA510(k)-cleared, CE-marked PharmaJet Needle-free Delivery System has demonstrated effective uptake of the SCIB1/SCIB1+ DNA vaccine in addition to offering speed, convenience, and an enhanced patient experience. The agreement reinforces PharmaJet’s strategy to be the best-in-class delivery system for novel DNA and RNA cancer immunotherapies.
“The Scancell strategic partnership further solidifies PharmaJet’s commercial delivery platform as a leader in the delivery of nucleic acid vaccines and immunotherapies,” said Nathalie Landry, CSO at PharmaJet. “We look forward to working with Scancell to advance their innovation further in clinical development and commercialization for the ultimate benefit of melanoma patients worldwide.”
To date, 60 patients across 15 clinical sites have successfully received a total of 171 doses of SCIB1/iSCIB1+ via Stratis. The combination of SCIB1/iSCIB1+ vaccine with Stratis offers patients the convenience of an off-the-shelf therapeutic cancer vaccine with the speed and enhanced patient experience of needle-free delivery.
“Securing long term supply for the PharmaJet Stratis Needle-free Injection System is important to allow clinical and commercial development of iSCIB1+. We are pleased that PharmaJet delivery works effectively with the SCIB1/iSCIB1+ therapeutic cancer vaccines and offers a well-received immunization for patients,” commented Professor Lindy Durrant, CEO of Scancell.
